Intalfa 3miu Injection contains Interferon Alpha 2B at a dosage of 3 million international units (3miu) per vial, a recombinant cytokine with antiviral, antiproliferative, and immunomodulatory properties. It is indicated for the treatment of chronic hepatitis B and C infections, certain malignancies such as hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi’s sarcoma, as well as for off-label use in other viral and neoplastic conditions as determined by a healthcare professional. Interferon Alpha 2B exerts its therapeutic effects by binding to specific cell surface receptors, activating intracellular signaling pathways that enhance the immune response and inhibit viral replication and tumor cell proliferation. Intalfa 3miu Injection is administered via subcutaneous or intramuscular injection, with dosing regimens tailored to the specific condition and patient response. Common adverse effects include flu-like symptoms, fatigue, myalgia, and hematologic abnormalities, necessitating regular monitoring of blood counts and liver function during therapy. Caution is advised in patients with autoimmune disorders, severe cardiac or psychiatric conditions, and pregnancy. Intalfa 3miu Injection should be used under strict medical supervision, ensuring appropriate patient selection, dosing, and monitoring to optimize therapeutic outcomes and minimize potential risks.